Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
Trial Parameters
Brief Summary
About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.
Eligibility Criteria
Inclusion Criteria: * Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma * \>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting * Platinum-free interval should be \>=6 months from the last dose of platinum-based chemotherapy * Upfront SCR not feasible * Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment. * Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment. Exclusion Criteria: * Non-epithelial or borderline tumors are excluded * Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded. * Patients using more than one line of chemotherapy are excluded. * Patients who have platinum-resis